52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Abbott And Sanofi Partner To Integrate Glucose Sensing And Insulin Delivery Technologies
Abbott Sets Quarterly Dividend Of $0.32 Per Share
Abbott CEO Says FreeStyle Libre Can Achieve $5 Bln In Sales "In A Reasonable Time"
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Medical Equipment & Supplies
100 Abbott Park Rd
Miles D. White
Chairman of the Board, Chief Executive Officer
Robert B. Ford
President, Chief Operating Officer
Brian B. Yoor
Chief Financial Officer, Executive Vice President - Finance
Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Abbott Laboratories <ABT.N> beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.
Abbott Laboratories <ABT.N> plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.
Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.
Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.
Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.
The U.S. Justice Department on Tuesday said it has joined a whistleblower lawsuit alleging Abbott Laboratories' Alere Inc unit defrauded Medicare into paying for unnecessary testing supplies for diabetic patients.
Alere Inc, now a unit of Abbott Laboratories Inc, has agreed to pay $20 million to resolve claims it made false and misleading statements to investors in the lead up to the announcement of a deal to sell the diagnostic testing company to Abbott.
Jan 25 - Abbott Laboratories has escaped a proposed class action lawsuit alleging its subsidiary St. Jude Medical concealed a potentially deadly battery defect in some of its cardiac defibrillators for years before finally recalling them in 2016.
Abbott Laboratories <ABT.N> missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.
Healthcare company Abbott Laboratories <ABT.N> will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.
Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.
Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.
Abbott Laboratories, the maker of Similac infant formula, has agreed to not falsely represent that surveys it mails new parents are for scientific research instead of marketing purposes and to accurately disclose their purpose.
Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
Abbott Laboratories and AbbVie Inc will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for them prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
Abbott Laboratories <ABT.N> reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.
Diversified healthcare company Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.
Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.
Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit.
Allergan Plc <AGN.N> said on Thursday former Abbott Laboratories <ABT.N> executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.